Davita Inc vs Fubotv Inc — how do they compare? Davita Inc trades at $231.77 (market cap $14.92B), while Fubotv Inc trades at $10.03 (market cap $280.89M). The key difference: Davita Inc is far larger — about 53.1× Fubotv Inc's market cap, and Davita Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| DVA | FUBO | |
|---|---|---|
Market Cap | $14.92B | $280.89M |
Sector | Health | Technology |
52-Week High | $235.71 | $54.72 |
52-Week Low | $103.87 | $8.09 |
Enterprise Value | $27.47B | $451.31M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
FUBO trades at $9.83, up 7.08% today, with technical indicators showing neutral signals. The company reported a net loss of $172.25M in 2024, but revenue grew to $1.62B and net income is projected to turn positive in 2025. Recent CEO appointment from Disney has driven positive sentiment, while valuation ratios like P/E of 2.56 and P/S of 0.2 appear attractive relative to historical norms.
Outlook is cautiously optimistic with analyst consensus price target of $16.25 implying 65% upside, supported by streaming growth and new partnerships. Key risks include persistent cash burn and intense competition in the streaming sector. The stock offers value if profitability targets are met, but requires monitoring of subscriber trends and execution on cost controls.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →